U
CADX

UBS’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

UBS’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,000
Closed -$27K – 11354
2013
Q4 		$27K Buy
3,000
+1,100
+58% +$7.94K ﹤0.01% 7801
2013
Q3 		$12K Buy
1,900
+900
+90% +$5.72K ﹤0.01% 8685
2013
Q2 		$7K Buy
+1,000
New +$6.97K ﹤0.01% 9069

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's CADX Position: Q1 2014 in Review

UBS sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 80,999 shares — an estimated $733K sold.

UBS first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $733K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • UBS reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • UBS sold 80,999 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $733K.
  • UBS first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • UBS's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $733K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on UBS's 13F filing for Q1 2014, filed 15 May 2014.